Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$105.9 million.

  • Denali Therapeutics' Free Cash Flow fell 68.06% to -$105.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$410.8 million, marking a year-over-year decrease of 9.36%. This contributed to the annual value of -$363.6 million for FY2024, which is 1.97% up from last year.
  • Per Denali Therapeutics' latest filing, its Free Cash Flow stood at -$105.9 million for Q3 2025, which was down 33.10% from -$79.6 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Free Cash Flow peaked at -$43.3 million during Q3 2021, and registered a low of -$136.5 million during Q1 2025.
  • Its 3-year average for Free Cash Flow is -$96.1 million, with a median of -$96.0 million in 2024.
  • Per our database at Business Quant, Denali Therapeutics' Free Cash Flow crashed by 6,885.32% in 2021 and then climbed by 29.53% in 2024.
  • Denali Therapeutics' Free Cash Flow (Quarterly) stood at -$68.5 million in 2021, then fell by 13.08% to -$77.5 million in 2022, then slumped by 30.16% to -$100.9 million in 2023, then grew by 11.98% to -$88.8 million in 2024, then tumbled by 68.06% to -$105.9 million in 2025.
  • Its Free Cash Flow was -$105.9 million in Q3 2025, compared to -$79.6 million in Q2 2025 and -$136.5 million in Q1 2025.